Fewer Adolescent Myocarditis Reports After COVID-19 Booster
Pharmacists should expect to get some questions or hear concerns about local and systemic reactions in adolescents aged 12 to 17 years after receiving the Pfizer-BioNTech booster vaccination, but serious adverse events have been rare and are generally mild to moderate. In fact, reports of myocarditis are lower than with the second vaccine in the initial series. Read more.

Pharmacy Clinics Expected to Offer COVID-19 "Test to Treat"
As the United States enters a new phase in the fight against the COVID-19 pandemic—for example, adding effective treatments to successful vaccination efforts—pharmacies will continue to play an outsized role and will become central players in the new National COVID-19 Preparedness Plan. Learn more about the White House "Test-to-Treat" initiative and how it involves pharmacy-based clinics.

Protecting Congenital Heart Defect Patients Against COVID-19
Having a congenital heart defect puts patients at higher risk of severe cases of COVID-19 or even death, according to a new study. Patients aged older than age 50 years and male sex heightens the risk. That is why the CDC is recommending that pharmacists and other healthcare professionals make sure the cohort takes appropriate precautions. Read more.